 |
| Modules | |
| Google | |
|
These ads help pay for the upkeep of our site. They are automatically served by Google and are not affiliated with This is MS. | |
| Languages | |
|
Select Interface Language:
| |
| Who's Online | |
There are currently, 210 guest(s) and 10 member(s) that are online.
You are Anonymous user. You can register for free by clicking here | |
| Next Step | |
| Donations | |
|
To remain unbiased, This is MS does not accept corporate sponsorships. Therefore, we must rely on our users to help support us. Please donate to our upkeep if you have the means. Thank you! | |
| |
 | News: Talk with Teva and Active Biotech about Laquinimod (Oral Therapy for MS) |
An open invitation from Active Biotech (laquinimod-- oral treatment for MS currently in trials) for their general MS update meeting with Teva (makers of Copaxone), who has partnered with them to bring laquinimod to market. Besides being informative on its own, this will give a rare chance to ask pointed questions about the MS drug pipeline from one of the leading companies coupled with one of the most promising. Note that this meeting will be held in Sweden, so adjust the start time appropriately.
"[Active Biotech] will, together with representatives from Teva senior management, inform on the companies' presence and activities in the multiple
sclerosis (MS) market.
An update of Active Biotech's other projects will also be given.
Date: Tuesday, October 19, 2004
Time: 13:00 - 15:00
Place: IVA (The Royal Swedish Academy of Engineering Sciences), Grev Turegatan 16, Stockholm
Kindly send your notification to participate, including name, company, telephone number and e-mail address, before October 12, to Susanne Jonsson,
Fax: +46 46 19 20 50 or susanne.jonsson@activebiotech.com"
Click "read more" for the background on this meeting...
Advertisement
Full Press Release
LUND, Sweden, Sept. 15 /PRNewswire/ --
Welcome to Active Biotech's capital
market meeting in Stockholm on October 19.
The company will, together with representatives from Teva senior
management, inform on the companies' presence and activities in the multiple
sclerosis (MS) market.
An update of Active Biotech's other projects will also be given.
Date: Tuesday, October 19, 2004
Time: 13:00 - 15:00
Place: IVA (The Royal Swedish Academy of Engineering Sciences), Grev
Turegatan 16, Stockholm
Kindly send your notification to participate, including name, company,
telephone number and e-mail address, before October 12, to Susanne Jonsson,
Fax: +46 46 19 20 50 or susanne.jonsson@activebiotech.com
Lund, September 15, 2004
Active Biotech AB (publ)
Sven Andreasson
President & CEO
For further information, please contact:
Cecilia Hofvander, Manager Corporate Communication
Phone: +46 46 19 11 22 or cecilia.hofvander@activebiotech.com
Background
On June 14, 2004, Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) and
Active Biotech signed an agreement to develop and commercialise laquinimod,
Active Biotech's novel immunomodulatory compound, which has the potential to
be an orally available disease modifying treatment of multiple sclerosis (MS).
The agreement gives Teva the exclusive rights to develop, register,
manufacture and commercialise laquinimod worldwide, with the exception of the
Nordic and Baltic countries, where Active Biotech will retain all commercial
rights.
Active Biotech AB is a biotechnology company focusing on research and
development of pharmaceuticals. Active Biotech has a strong R&D portfolio and
pipeline products with focus primarily on autoimmune/ inflammatory diseases
and cancer. Most advanced projects include orally administered small molecules
with unique immunomodulatory properties that can be used to treat autoimmune
and inflammatory diseases, as well as a novel concept for use in cancer
immunotherapy.
Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the
top 25 pharmaceutical companies and among the largest generic pharmaceutical
companies in the world. The company develops, manufactures, and markets
generic and innovative human pharmaceuticals and active pharmaceutical
ingredients. Close to 90 percent of Teva's sales are in North America and
Europe. Teva's innovative R&D focuses on developing novel drugs for diseases
of the central nervous system. Copaxone(R), Teva's innovative product for the
treatment of Relapse Remitting Multiple Sclerosis is marketed mainly in the
U.S. and Europe and has market share of more than 30% in terms of
prescriptions in the U.S. where it is also the second most prescribed
treatment. Copaxone(R) is approved in 43 countries worldwide.
Active Biotech AB
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 20 50
http://www.activebiotech.com
http://hugin.info/1002/R/960749/138475.pdf
SOURCE Active Biotech
Web Site: http://www.activebiotech.com
|
|
|
|
| |
| Login | |
|
Don't have an account yet? You can create one. As a registered user you have some advantages like theme manager, comments configuration and post comments with your name. | |
| Related Links | |
| Article Rating | |
Average Score: 4
Votes: 2
| |
| Options | |
|
Associated Topics
 |
|
|
|
